Epithalon Dosage: The Studied Numbers and Why They Are Uncertain
Epithalon, also called epitalon or AEDG, has promising cell research and limited human studies. But the familiar 5–10 mg injection cycle is not an established longevity or insomnia treatment. This guide separates actual study contexts from community schedules, checks the arithmetic and brings together the original and newer research.
The dose used in the research
There is no established epithalon dose for extending human lifespan or treating insomnia. The familiar 5–10 mg daily injection courses should be identified as online/community protocols, not attributed to a validated human dose-ranging program. Different substances and routes have been mixed together in retellings of the research.
One human study evaluated a much smaller amount by a different route: Ivko and colleagues (2021) studied melatonin-related biomarkers. The FDA review of its methods describes 0.5 mg/day sublingually for 20 days in the active group, compared with placebo. Participants were middle-aged women primarily working night shifts, not an insomnia-treatment population. That is study context, not a substitute prescription or an injection conversion.
Reconstitution and the practical math
Concentration arithmetic can be checked without selecting a dose or preparation method. The examples below assume the stated mass is present in the final solution volume, which need not equal the amount of liquid added:
- 50 mg in a final 5 mL = 10 mg/mL. A hypothetical 5 mg amount occupies 0.5 mL; 10 mg occupies 1 mL.
- 10 mg in a final 2 mL = 5 mg/mL. A hypothetical 5 mg amount occupies 1 mL.
- On a U-100 syringe specifically, 1 mL corresponds to 100 units; 0.5 mL corresponds to 50 units. Other syringe calibrations differ, and units are not automatically the number of graduation lines.
These examples do not validate injecting either amount. No universal choice of bacteriostatic water, mixing technique, refrigeration period or beyond-use date follows from the math. Product-specific preparation and storage information must come from the dispensing professional; a research label does not establish suitability for injection. The reconstitution guide, peptide calculator and storage guide explain the related distinctions.
Course length and cycling
Ten-to-twenty-day courses repeated once or twice a year are discussed in online protocols. The sources reviewed do not establish those patterns as effective subcutaneous treatment schedules. A study lasting 20 days does not establish how often to repeat it, and epithalamin extract schedules cannot be transferred automatically to synthetic epitalon.
Neither a claimed short circulating half-life nor a proposed gene-regulatory mechanism determines a clinical cycling interval. The available evidence does not validate continuous-versus-intermittent use, scheduled breaks to prevent tolerance, or an annual longevity regimen.
Route: what was actually studied
Injection is not the only route represented in human publications. Alongside the sublingual work above, a 2002 retinitis-pigmentosa report studied epitalon in a specialist eye-treatment setting. The FDA literature review identifies its route as parabulbar, around the eye—not a routine subcutaneous longevity injection.
Sublingual administration is not the same as swallowing a capsule or using a nasal spray. Neither that study nor an eye-treatment report supplies a validated conversion among routes. Convenience, peptide size or numerical similarity cannot establish equivalent exposure, efficacy or safety.
The epithalamin confusion that inflates the evidence
Epithalamin is a pineal-gland polypeptide extract; epithalon/epitalon is the defined tetrapeptide Ala-Glu-Asp-Gly (AEDG). Their related research history does not make them interchangeable.
The 2003 long-term human report by Khavinson and Morozov concerned epithalamin and thymalin preparations. Its favorable mortality observations should not be credited to synthetic AEDG. At the same time, it would be inaccurate to dismiss all human epitalon findings as extract studies: the sublingual biomarker and retinal reports concern the synthetic peptide.
The telomerase claim, at its source
The 2003 Khavinson laboratory experiment reported telomerase activation and telomere elongation in cultured human fibroblasts. A 2004 follow-up reported additional cell divisions beyond the usual limit. These are cell-culture results, not human lifespan trials.
The evidence is no longer confined to that original group. Al-dulaimi and colleagues at Brunel and Royal Brompton (2025) reported telomere-length effects in normal and breast-cancer cell lines, involving telomerase upregulation in normal cells and alternative lengthening of telomeres (ALT) in cancer cells. The journal published a November 2025 figure correction; readers should use the corrected article.
This newer work strengthens the preclinical basis for studying telomere effects. It does not show that epitalon extends a person’s life, prevents cancer or causes cancer in users. A cellular mechanism cannot settle those clinical outcomes. See peptides for longevity and peptides for anti-aging for the broader context.
The melatonin and sleep angle
The 2021 AEDG study reported increased urinary 6-sulfatoxymelatonin and changes in circadian-gene expression. These are promising human biomarker findings and are not simply epithalamin extract results. They do not establish improved sleep duration, sleep quality or remission of clinical insomnia.
Our sleep guide discusses related evidence; it is not a ranking of proven epitalon substitutes. Pinealon is a different peptide and should not be treated as the same product.
Safety, legality and supply
Good tolerability at 5–10 mg is not established by the human sources reviewed. Missing or limited adverse-event reporting cannot demonstrate safety, especially for repeated subcutaneous courses. Cell findings also cannot define a safe dose in people.
In the US, epitalon is not FDA-approved. The July 2026 advisory meeting considered free-base and acetate substances for compounding in the context of insomnia. Advisory consideration is not drug approval or a final rule. Do not infer the legal eligibility or quality of an individual formulation from a research label, an online listing or a committee discussion.
Compounding can meet legitimate patient needs under applicable conditions; the FDA explanation distinguishes that practice from drug approval. Ask the clinician and dispensing pharmacist about current requirements and the exact product. This guide does not make a worldwide legality claim. See legal status of research peptides, FDA-approved peptides, and injection background; technique does not establish that epitalon should be injected. Related reading: epitalon overview and epithalon vs MOTS-c.
The bottom line
Epitalon has genuine cell research, newer independent mechanistic findings and limited human biomarker and retinal reports. None establishes the familiar 5–10 mg subcutaneous longevity cycle. Keep the promising findings, but match each conclusion to the exact substance, route, population and outcome. Concentration math is independently checkable; a treatment dose requires clinical evidence and individualized judgment.
Frequently Asked Questions About Epithalon
There is no established epitalon dose for human longevity or insomnia. The familiar 5–10 mg daily injection cycles are online/community protocols, not a validated dose-ranging result. A human biomarker study used 0.5 mg/day sublingually for 20 days; that is a different route and outcome, not an injection conversion or prescription.
No universal preparation recipe is established here. As arithmetic only, 50 mg in a final 5 mL gives 10 mg/mL: 0.5 mL contains 5 mg. Ten mg in a final 2 mL gives 5 mg/mL: 1 mL contains 5 mg. These examples do not select a dose, diluent, sterility method or shelf life. Final volume need not equal liquid added.
Ten-to-twenty-day courses repeated once or twice yearly are not established longevity schedules by the sources reviewed. A short study duration does not determine a repeat interval. Extract schedules and proposed mechanisms cannot validate a synthetic epitalon cycling protocol.
Neither injection nor nasal spray has an established advantage for longevity or insomnia from the sources reviewed. Human publications include sublingual administration and specialist parabulbar eye treatment. Those are not evidence for routine subcutaneous dosing, and no route conversion is established here.
Studies reported telomere effects in cultured human cells, including the original 2003 research and a separate 2025 study. This supports further investigation, not a conclusion that epitalon lengthens life in people. The newer paper has a published figure correction.
No. Epithalamin is a pineal-gland polypeptide extract; epitalon is the defined synthetic tetrapeptide AEDG. Favorable long-term extract observations cannot be assigned to AEDG, although limited human studies of the synthetic peptide also exist.
Epitalon is not FDA-approved in the US. The July 2026 advisory process considered its free-base and acetate forms for compounding; advisory activity is not approval or a final rule. An individual product’s eligibility and quality require separate assessment. This guide does not assert worldwide status or that every product is lawfully available.